Publications

  1. Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2025 May 2; JCO2500007 Epub 2025 May 02
    View PubMed
  2. Asiri IM, Chen RC, Master V, Mi L, James SE, Bryce AH, Afzal U, Riaz IB, Ahmed Naqvi SA, Beach SRH, Cobran EK. Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors. Prostate. 2025 May 1 Epub 2025 May 01
    View PubMed
  3. Asiri IM, Chen RC, Master V, Mi L, James SE, Odedina FT, Bryce AH, Tilburt JC, Riaz IB, Naqvi SAA, Abraham V, Beach SRH, Cobran EK. Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients. Cancer Epidemiol. 2025 Apr; 95:102769 Epub 2025 Feb 12
    View PubMed
  4. Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2025 Mar; 28 (1):138-144 Epub 2024 Feb 10
    View PubMed
  5. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Eur Urol. 2025 Jan 22 [Epub ahead of print]
    View PubMed
  6. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 1; 131 (1):e35612 Epub 2024 Dec 01
    View PubMed
  7. Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncol Pract. 2024 Dec 19; OP2400626 [Epub ahead of print]
    View PubMed
  8. Barnett RM, Jang A, Lanka S, Fu P, Bucheit LA, Babiker H, Bryce A, Meyer HM, Choi Y, Moore C, Garje R, Gao X, Kim DW, Chang RY, Gulhati P, Ramaker R, Bansal R, Zhang T, Oliver Sartor A, Armstrong AJ, Bilen MA, Barata P. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. Commun Med (Lond). 2024 Dec 2; 4 (1):256 Epub 2024 Dec 02
    View PubMed
  9. Meyer H, Sunkara R, Rothmann E, Shah A, Riaz I, Courtney KD, Armstrong AJ, Lippucci A, Naqvi SAA, Stanton ML, Beltran H, Bryce AH. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate. Clin Genitourin Cancer. 2024 Oct; 22 (5):102172 Epub 2024 Aug 06
    View PubMed
  10. Serritella AV, Taylor A, Haffner MC, Abida W, Bryce A, Karsh LI, Tagawa ST, Twardowski P, Armstrong AJ, Lang JM. Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). Prostate Cancer Prostatic Dis. 2024 Sep 27 Epub 2024 Sept 27
    View PubMed
  11. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2024 Aug; 7 (4):877-887 Epub 2023 Dec 09
    View PubMed
  12. Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, Karnes RJ, Kwon ED, Childs DS, Andrews JR. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27 (2):334-338 Epub 2023 Nov 07
    View PubMed
  13. Saxena A, Andrews J, Bryce AH, Riaz IB. Optimal systemic therapy in men with low-volume prostate cancer. Curr Opin Urol. 2024 May 1; 34 (3):183-197 Epub 2024 Mar 05
    View PubMed
  14. Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 1; 42 (10):1114-1123 Epub 2024 Jan 23
    View PubMed
  15. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2 (4) Epub 2024 Apr 15
    View PubMed
  16. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr; 2 (4) Epub 2024 Apr 15
    View PubMed
  17. Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, Cookson MS, McKay RR, Bryce AH, Kaymakcalan MD. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Mar 2 Epub 2024 Mar 02
    View PubMed
  18. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Oct; 21 (10):1067-1096
    View PubMed
  19. Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 Sep; 84 (3):321-330 Epub 2023 June 03
    View PubMed
  20. Ng CT, Bonilla HMG, Bryce AH, Singh P, Herrmann J. Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer. Curr Cardiol Rep. 2023 Aug; 25 (8):889-899 Epub 2023 July 25
    View PubMed
  21. Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study. Clin Genitourin Cancer. 2023 Aug; 21 (4):483-490 Epub 2023 Apr 24
    View PubMed
  22. Bryce AH, Thiel DD, Seiden MV, Richards D, Luan Y, Coignet M, Zhang Q, Zhang N, Hubbell E, Kurtzman KN, Klein EA. Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers. JCO Precis Oncol. 2023 Jul; 7:e2200679
    View PubMed
  23. Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). J Clin Oncol. 2023 Jun 20; 41 (18):3352-3362 Epub 2023 Mar 30
    View PubMed
  24. Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023 May 1; 9 (5):635-645
    View PubMed
  25. Sarkar S, Min K, Ikram W, Tatton RW, Riaz IB, Silva AC, Bryce AH, Moore C, Ho TH, Sonpavde G, Abdul-Muhsin HM, Singh P, Wu T. Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach. Cancers (Basel). 2023 Mar 8; 15 (6) Epub 2023 Mar 08
    View PubMed
  26. Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang NJ, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, Watkins S, King C, Nguyen M, Simmons AD, Chowdhury S, Abida W. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. 2023 Mar; 83 (3):200-209 Epub 2022 Oct 13
    View PubMed
  27. Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nole F, Staffurth J, Redfern C, Saez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH, TRITON3 Investigators. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23; 388 (8):719-732 Epub 2023 Feb 16
    View PubMed
  28. Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2023 Feb; 83(3):227-236. Epub 2022 Nov 16.
    View PubMed
  29. Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. JAMA Oncol. 2023 Feb 1; 9 (2):180-187
    View PubMed
  30. Budhraja KK, McDonald BR, Stephens MD, Contente-Cuomo T, Markus H, Farooq M, Favaro PF, Connor S, Byron SA, Egan JB, Ernst B, McDaniel TK, Sekulic A, Tran NL, Prados MD, Borad MJ, Berens ME, Pockaj BA, LoRusso PM, Bryce A, Trent JM, Murtaza M. Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. Sci Transl Med. 2023 Jan 11; 15 (678):eabm6863
    View PubMed
  31. Phan T, Weber A, Bryce AH, Kuang Y. The prognostic value of androgen to PSA ratio in predictive modeling of prostate cancer. Medical Hypotheses. 2023; 176:111084
  32. Thomson HM, Fortin Ensign SP, Edmonds VS, Sharma A, Butterfield RJ 3rd, Schild SE, Ashman JB, Zimmerman RS, Patel NP, Bryce AH, Vora SA, Sio TT, Porter AB. Clinical Outcomes of Stereotactic Radiosurgery-Related Radiation Necrosis in Patients with Intracranial Metastasis from Melanoma. Clin Med Insights Oncol. 2023; 17:11795549231161878. Epub 2023 Mar 21.
    View PubMed
  33. Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, Gross S, Melton C, Fields AP, Liu Q, Zhang N, Fung ET, Kurtzman KN, Amini H, Betts C, Civello D, Freese P, Calef R, Davydov K, Fayzullina S, Hou C, Jiang R, Jung B, Tang S, Demas V, Newman J, Sakarya O, Scott E, Shenoy A, Shojaee S, Steffen KK, Nicula V, Chien TC, Bagaria S, Hunkapiller N, Desai M, Dong Z, Richards DA, Yeatman TJ, Cohn AL, Thiel DD, Berry DA, Tummala MK, McIntyre K, Sekeres MA, Bryce A, Aravanis AM, Seiden MV, Swanton C. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022 Dec 12; 40 (12):1537-1549.e12 Epub 2022 Nov 17
    View PubMed
  34. Sicotte H, Kalari KR, Qin S, Dehm SM, Bhargava V, Gormley M, Tan W, Sinnwell JP, Hillman DW, Li Y, Vedell PT, Carlson RE, Bryce AH, Jimenez RE, Weinshilboum RM, Kohli M, Wang L. Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Mol Cancer Res. 2022 Dec 2; 20 (12):1739-1750
    View PubMed
  35. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec; 20 (12):1288-1298
    View PubMed
  36. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):684-692 Epub 2022 July 22
    View PubMed
  37. Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ, ECOG-ACRIN E3805 Investigators. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate. 2022 Sep; 82 (12):1176-1185 Epub 2022 May 10
    View PubMed
  38. Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02.
    View PubMed
  39. Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22
    View PubMed
  40. Riaz IB, Islam M, Khan AM, Naqvi SAA, Siddiqi R, Khakwani KZR, Asghar N, Ikram W, Hussain SA, Singh P, Warner JL, Sonpavde GP, Odedina FT, Kehl KL, Duma N, Bryce AH. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. Am J Med. 2022 Aug; 135 (8):984-992.e6 Epub 2022 Apr 25
    View PubMed
  41. Riaz IB, Sipra QUAR, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022 Jul; 175:103706. Epub 2022 May 07.
    View PubMed
  42. Karp DD, Camidge DR, Infante JR, Ames TD, Price MR, Jimeno J, Bryce AH. Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. EClinicalMedicine. 2022 Jul; 49:101430 Epub 2022 May 27
    View PubMed
  43. Qin S, Gao H, Kim W, Zhang H, Gu Y, Kalari KR, Sinnwell JP, Scholz JA, Xie F, Yin P, Yu J, Qin B, Zhuang Y, Wei L, Tan W, Bryce AH, Weinshilboum RM, Wang L. Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer. Clin Pharmacol Ther. 2022 Jun; 111 (6):1296-1306 Epub 2022 Apr 12
    View PubMed
  44. Riaz IB, Fuentes HE, Naqvi SAA, He H, Sipra QR, Tafur AJ, Padranos L, Wysokinski WE, Marshall AL, Vandvik PO, Montori V, Bryce AH, Liu H, Badgett RG, Murad MH, McBane RD 2nd. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2022 Feb; 97 (2):308-324 Epub 2021 June 22
    View PubMed
  45. Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A. Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Manag Res. 2022; 14:673-686 Epub 2022 Feb 17
    View PubMed
  46. Jimbo M, Andrews JR, Ahmed ME, Dundar A, Karnes RJ, Bryce AH, Kendi AT, Kwon ED, Lowe VJ, Bold MS. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate. 2022 Jan; 82(1):41-48. Epub 2021 Oct 11.
    View PubMed
  47. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727 Epub 2022 Sept 28
    View PubMed
  48. Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. Clin Cancer Res 2021 Dec 15; 27 (24):6677-6686 Epub 2021 Oct 01
    View PubMed
  49. Riaz IB, He H, Ryu AJ, Siddiqi R, Naqvi SAA, Yao Y, Husnain M, Narasimhulu DM, Mathew J, Sipra QUAR, Vandvik PO, Joseph RW, Liu H, Wang Z, Herasevich V, Singh P, Hussain SA, Ho TH, Bryce AH, Pagliaro LC, Murad MH, Costello BA. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. Eur Urol. 2021 Dec; 80 (6):712-723 Epub 2021 Apr 03
    View PubMed
  50. Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncol Pract. 2021 Sep; 17 (9):e1382-e1393 Epub 2021 June 14
    View PubMed
  51. Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 5; 5 (1):74 Epub 2021 Aug 05
    View PubMed
  52. He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021 Jul 15; 131(14).
    View PubMed
  53. Francini E, Montagnani F, Nuzzo PV, Gonzalez-Velez M, Alimohamed NS, Rosellini P, Moreno-Candilejo I, Cigliola A, Rubio-Perez J, Crivelli F, Shaw GK, Zhang L, Petrioli R, Bengala C, Francini G, Garcia-Foncillas J, Sweeney CJ, Higano CS, Bryce AH, Harshman LC, Lee-Ying R, Heng DYC. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021 Jul 1; 4 (7):e2116536 Epub 2021 July 01
    View PubMed
  54. Bilal J, Riaz IB, Naqvi SAA, Bhattacharjee S, Obert MR, Sadiq M, Abd El Aziz MA, Nooman Y, Prokop LJ, Ge L, Murad MH, Bryce AH, McBane RD, Kwoh CK. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 Jul; 96 (7):1861-1873 Epub 2021 Apr 09
    View PubMed
  55. Freitag CE, Sukov WR, Bryce AH, Berg JV, Vanderbilt CM, Shen W, Smadbeck JB, Greipp PT, Ketterling RP, Jenkins RB, Herrera-Hernandez L, Costello BA, Thompson RH, Boorjian SA, Leibovich BC, Jimenez RE, Murphy SJ, Vasmatzis G, Cheville JC, Gupta S. Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Hum Pathol. 2021 Jun; 112:20-34 Epub 2021 Mar 31
    View PubMed
  56. Ledet EM, Burgess EF, Sokolova AO, Jaeger EB, Hatton W, Moses M, Miller P, Cotogno P, Layton J, Barata P, Lewis BE, Nakazawa M, Zhu J, Dellinger B, Elrefai S, Nafissi NN, Egan JB, Shore N, McKay RR, Bryce AH, Cheng HH, Antonarakis ES, Sartor O. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate. 2021 May; 81(7):433-439. Epub 2021 Apr 01.
    View PubMed
  57. Crawford ED, Kane CJ, Harris RG, Bryce AH, Petrylak DP. Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer. Oncology (Williston Park). 2021 Apr 19; 35 (4):166
    View PubMed
  58. Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist. 2021 Feb; 26 (2):e270-e278 Epub 2020 Dec 03
    View PubMed
  59. Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, Kunze KL, Golafshar M, Uson PLS Jr, Mountjoy L, Ertz-Archambault N, Patel N, Rodriguez EA, Lizaola-Mayo B, Lehrer M, Thorpe CS, Yu NY, Esplin ED, Nussbaum RL, Sharp RR, Azevedo C, Klint M, Hager M, Macklin-Mantia S, Bryce AH, Bekaii-Saab TS, Sekulic A, Stewart AK. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021 Feb 1; 7 (2):230-237
    View PubMed
  60. Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2021; 5. Epub 2021 Jul 22.
    View PubMed
  61. LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS One. 2021; 16 (4):e0248097 Epub 2021 Apr 07
    View PubMed
  62. Bangalore Kumar A, Bryce AH, Vishnu P, Markovic SN, McEvoy MT. Associations of cutaneous immune-related adverse effects of immunotherapy with treatment response in patients with metastatic melanoma. SKIN: Journal of Cutaneous Medicine. 2021; 5 (2):108-17
  63. Padrnos LJ, Houghton OM, Iacob CE, Kurli M, Ocal IT, Bryce AH. Genomic profiling proves metastasis of cutaneous melanoma to vitreal fluid. Melanoma Res. 2020 Dec; 30 (6):590-593
    View PubMed
  64. Bryce AH, Chen YH, Liu G, Carducci MA, Jarrard DM, Garcia JA, Dreicer R, Hussain M, Eisenberger MA, Plimack ER, Vogelzang NJ, DiPaola RS, Harshman L, Sweeney CJ. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol. 2020 Dec; 3 (6):717-724 Epub 2020 Aug 15
    View PubMed
  65. Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho T, Singh P, Bryce AH. Evolving Natural History of Metastatic Prostate Cancer. Cureus. 2020 Nov 14; 12 (11):e11484
    View PubMed
  66. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S, TRITON2 investigators. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 2020 Nov 10; 38 (32):3763-3772 Epub 2020 Aug 14
    View PubMed
  67. Zarei S, Voss JS, Jin L, Jenkins SM, Bryce AH, Erickson LA, Bell DA, Kipp BR, Flotte TJ. Mutational Profile in Vulvar, Vaginal, and Urethral Melanomas: Review of 37 Cases With Focus on Primary Tumor Site. Int J Gynecol Pathol. 2020 Nov; 39 (6):587-594
    View PubMed
  68. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin Proc. 2020 Sep; 95 (9):1989-1999 Epub 2020 July 19
    View PubMed
  69. Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020 Aug; 8(2).
    View PubMed
  70. Abida W, Campbell D, Patnaik A, Shapiro JD, Sautois B, Vogelzang NJ, Voog EG, Bryce AH, McDermott R, Ricci F, Rowe J, Zhang J, Piulats JM, Fizazi K, Merseburger AS, Higano CS, Krieger LE, Ryan CJ, Feng FY, Simmons AD, Loehr A, Despain D, Dowson M, Green F, Watkins SP, Golsorkhi T, Chowdhury S. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clin Cancer Res 2020 Jun 1; 26 (11):2487-2496 Epub 2020 Feb 21
    View PubMed
  71. Tanaka T, Yang M, Froemming AT, Bryce AH, Inai R, Kanazawa S, Kawashima A. Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review. Radiographics. 2020 May-Jun; 40 (3):709-726 Epub 2020 Mar 20
    View PubMed
  72. Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? Prostate. 2020 Apr; 80 (5):399-406 Epub 2020 Jan 13
    View PubMed
  73. Phan T, Crook SM, Bryce AH, Maley CC, Kostelich EJ, Kuang Y. Review: Mathematical modeling of prostate cancer and clinical application Applied Sciences. 2020; 10 (8):2721
  74. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020; 4:370-381 Epub 2020 Apr 21
    View PubMed
  75. McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020 Jan; 20 (1):101-109 Epub 2019 Nov 21
    View PubMed
  76. DeLeon TT, Almquist DR, Kipp BR, Langlais BT, Mangold A, Winters JL, Kosiorek HE, Joseph RW, Dronca RS, Block MS, McWilliams RR, Kottschade LA, Rumilla KM, Voss JS, Seetharam M, Sekulic A, Markovic SN, Bryce AH. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. PLoS One. 2020; 15 (3):e0230306 Epub 2020 Mar 20
    View PubMed
  77. Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019 Oct; 76 (4):452-458 Epub 2019 Feb 21
    View PubMed
  78. Faraj KS, Abdul-Muhsin HM, Navaratnam AK, Rose KM, Stagg J, Ho TH, Bryce AH, Cheney SM, Tyson MD, Castle EP. Role of robot-assisted retroperitoneal lymph node dissection in malignant mesothelioma of the tunica vaginalis: case series and review of the literature. Can J Urol. 2019 Jun; 26 (3):9752-9757
    View PubMed
  79. Bryce AH, Egan JB, Smadbeck JB, Johnson SH, Murphy SJ, Harris FR, Halling GC, Terra SBSP, Cheville J, Pagliaro L, Leibovich B, Costello BA, Vasmatzis G. Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. Sci Rep. 2019 Mar 5; 9 (1):3586 Epub 2019 Mar 05
    View PubMed
  80. Yap KK, Wong W, Ji L, Groshen S, Quinn DI, Bryce AH, Dorff TB. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. Cancer Treat Res Commun. 2019; 18:100114 Epub 2018 Nov 10
    View PubMed
  81. Barrett MT, Lenkiewicz E, Malasi S, Stanton M, Slack J, Andrews P, Pagliaro L, Bryce AH. Clonal analyses of refractory testicular germ cell tumors. PLoS One. 2019; 14 (3):e0213815 Epub 2019 Mar 14
    View PubMed
  82. DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018 Dec; 9 (6):1054-1062
    View PubMed
  83. Karp DD, Camidge DR, Infante JR, Ames TD, Jimeno JM, Bryce AH. PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors. Ann Oncol. 2018 Oct; 29 Suppl 8:viii143
    View PubMed
  84. Abida W, Bryce AH, Vogelzang NJ, Amato RJ, Percent I, Shapiro JD, McDermott R, Hussain A, Patnaik A, Petrylak D, Ryan CJ, Stanton T, Zhang J, Simmons AD, Despain D, Collins M, Golsorskhi T, Scher HI, Chowdhury S. Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2018 Oct; 29 Suppl 8:viii272
    View PubMed
  85. Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018 May 9; 8 (1):7375 Epub 2018 May 09
    View PubMed
  86. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Monnat RJ Jr, Xiao Y, Wang C, Cancer Genome Atlas Research Network. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018 Apr 3; 23 (1):239-254.e6
    View PubMed
  87. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C, Cancer Genome Atlas Research Network. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 Apr 3; 23 (1):194-212.e6
    View PubMed
  88. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Liu W, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG, Spellman PT, Rathmell WK, Linehan WM, Cancer Genome Atlas Research Network. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Apr 3; 23 (1):313-326.e5
    View PubMed
  89. Huang YL, Bryce AH, Culbertson T, Connor SL, Looker SA, Altman KM, Collins JG, Stellner W, McWilliams RR, Moreno-Aspitia A, Ailawadhi S, Mesa RA. Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction. J Oncol Pract. 2018 Feb; 14 (2):e82-e91 Epub 2017 Dec 22
    View PubMed
  90. McWilliams RR, Allred JB, Slostad JA, Katipamula R, Dronca RS, Rumilla KM, Erickson LA, Bryce AH, Joseph RW, Kottschade LA, King DM, Leitch JM, Markovic SN. NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma. Cancer. 2018 Feb 1; 124 (3):537-545 Epub 2017 Oct 17
    View PubMed
  91. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 01; 29(2):352-360.
    View PubMed
  92. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):e969-e975. Epub 2017 Apr 26.
    View PubMed
  93. Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD. Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clin Genitourin Cancer. 2017 Aug; 15 (4):e727-e734 Epub 2016 Dec 01
    View PubMed
  94. Conroy M, Borad MJ, Bryce AH. Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus. 2017 Jul 26; 9 (7):e1517 Epub 2017 July 26
    View PubMed
  95. Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017 Jun; 20 (2):221-227 Epub 2017 Jan 24
    View PubMed
  96. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 2017 Apr 18; 8 (16):27145-27154
    View PubMed
  97. Ho TH, Nunez-Nateras R, Hou YX, Bryce AH, Northfelt DW, Dueck AC, Wong B, Stanton ML, Joseph RW, Castle EP. A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Apr; 15 (2):196-202.e1 Epub 2016 Sept 08
    View PubMed
  98. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13. Epub 2017 Feb 01.
    View PubMed
  99. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
    View PubMed
  100. Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH. Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep. 2016 Dec 23; 6 (1):25
    View PubMed
  101. Bryce AH, Antonarakis ES. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations. Int J Urol. 2016 Aug; 23 (8):646-53 Epub 2016 June 03
    View PubMed
  102. Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016 Apr 15; 6(4):e010332.
    View PubMed
  103. Jain T, Bryce A. Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma. Cureus. 2015 Dec 16; 7 (12):e410
    View PubMed
  104. Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunol Res. 2015 Dec; 3 (12):1303-7 Epub 2015 Aug 25
    View PubMed
  105. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Nov 05; 163: (4)1011-25.
    View PubMed
  106. LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. Mol Cancer Ther. 2015 Aug; 14 (8):1962-71 Epub 2015 June 10
    View PubMed
  107. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015 Apr; 16 (4):375-84 Epub 2015 Mar 18
    View PubMed
  108. Hart SN, Moore RM, Zimmermann MT, Oliver GR, Egan JB, Bryce AH, Kocher JA. PANDA: pathway and annotation explorer for visualizing and interpreting gene-centric data. PeerJ. 2015; 3:e970 Epub 2015 May 19
    View PubMed
  109. Ho TH, Nateras RN, Yan H, Park JG, Jensen S, Borges C, Lee JH, Champion MD, Tibes R, Bryce AH, Carballido EM, Todd MA, Joseph RW, Wong WW, Parker AS, Stanton ML, Castle EP. A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS One. 2015; 10 (7):e0132831 Epub 2015 July 16
    View PubMed
  110. Bryce A. Do I need Chemotherapy for my Prostate Cancer? about.com. http://prostatecancer.about.com/od/treatment/fl/Do-I-need-Chemotherapy-for-my-Prostate-Cancer.htm. 2014 Aug 05.
  111. McCormick JB, Sharp RR, Farrugia G, Lindor NM, Babovic-Vuksanovic D, Borad MJ, Bryce AH, Caselli RJ, Ferber MJ, Johnson KJ, Lazaridis KN, McWilliams RR, Murray JA, Parker AS, Schahl KA, Wieben ED. Genomic medicine and incidental findings: balancing actionability and patient autonomy. Mayo Clin Proc 2014 Jun; 89 (6):718-21
    View PubMed
  112. Tyson MD 2nd, Bryce AH, Ho TH, Carballido EM, Castle EP. Perioperative complications after neoadjuvant chemotherapy and radical cystectomy for bladder cancer. Can J Urol. 2014 Jun; 21 (3):7259-65
    View PubMed
  113. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10.
    View PubMed
  114. Liang WS, Aldrich J, Nasser S, Kurdoglu A, Phillips L, Reiman R, McDonald J, Izatt T, Christoforides A, Baker A, Craig C, Egan JB, Chase DM, Farley JH, Bryce AH, Stewart AK, Borad MJ, Carpten JD, Craig DW, Monk BJ. Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing. Int J Gynecol Cancer. 2014 Feb; 24 (2):329-38
    View PubMed
  115. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13
    View PubMed
  116. Bryce AH, McWilliams R. Current status and future directions of personalized medicine. Genome Med. 2013; 5 (7):62 Epub 2013 July 29
    View PubMed
  117. Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. 2012 Oct; 30 (5):1934-41 Epub 2011 Sept 01
    View PubMed
  118. Bryce A, Ryan CJ. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin Pharmacol Ther. 2012 Jan; 91(1):101-8. Epub 2011 Nov 30.
    View PubMed
  119. Bryce AH, Mattar B, Hillman SL, Adjei AA, Kugler JW, Rowland K Jr, Wender DB, Soori G, Perez EA, Jett JR. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. Am J Clin Oncol. 2010 Aug; 33 (4):353-7
    View PubMed
  120. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94 (3):380-6 Epub 2009 Feb 11
    View PubMed
  121. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83 (11):840-1
    View PubMed
  122. Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008 May; 80 (5):397-406 Epub 2008 Jan 23
    View PubMed
  123. Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, Kumar SK, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma. 2006 Sep; 7(2):140-4.
    View PubMed
  124. Bryce AH, Kyle RA, Dispenzieri A, Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol. 2006 Jul; 81(7):511-8.
    View PubMed